Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 25

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jul 7, 2021; 27(25): 3762-3779
Published online Jul 7, 2021. doi: 10.3748/wjg.v27.i25.3762

Table 3 Available vaccines

	Company	Antigen - Adjuvant	Posology	Dosing
Engerix-B^®	GlaxoSmithKline	Rec. major S Ag (yeast) Aluminum	1 mL	3- or 4-dose
			20 mcg	0-1-6 mo
				0-7 d-21 d-12 mo
HBVaxPRO^®	Sanofi-Pasteur MSD	Rec. major S Ag (yeast) Aluminum	1 mL	3- or 4-dose
			5 mcg	0-1-6 mo
			10 mcg	0-1-2-12 mo
			40 mcg
Fendrix^®	GlaxoSmithKline	Rec. major S Ag (yeast) Aluminum + 3-O-desacyl-4 - monophosphoryl lipid A	0.5 mL	4-dose
Fendrix^®	GlaxoSmithKline		20 mcg	0-1-2-6 mo
Heplisav-B^®	Dynavax	Rec. major S Ag (yeast) HepB-CpG ligand	0.5 mL	2-dose
Heplisav-B^®	Dynavax	Rec. major S Ag (yeast) HepB-CpG ligand	20 mcg	0-1 mo
Twinrix^®	GlaxoSmithKline	In.HAV + Rec. major S Ag (yeast) Aluminum	1 mL	3-dose
			720/20 mcg	0-7-21 d
				0-1-6 mo
Sci-B-Vac^®	VBI Vaccines	Major S Ag, minor pre-S1 + pre-S2 Ag (mammalian cell) Aluminum	1 mL	3-dose
Sci-B-Vac^®	VBI Vaccines		10 mcg	0-1-6 mo
Pediarix^®	GlaxoSmithKline	DTaP + inactivated poliovirus + Rec.S (yeast) Aluminum	0.5 Ml	3-dose
Pediarix^®	GlaxoSmithKline	DTaP + inactivated poliovirus + Rec.S (yeast) Aluminum	10 mcg	(6-8 wk interval)

Ag: Antigen; DTaP: Diphtheria-tetanus-whooping cough (pertussis); In.HAV: Inactivated hepatitis A virus; Rec.: Recombinant.

Citation: Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779
URL: https://www.wjgnet.com/1007-9327/full/v27/i25/3762.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i25.3762

Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.